Rodney Smith, MD
General Practice · Gainesville, GANPI 1144290917
Payments from drug & device makers
Across 219 payments — averaging $12.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$432
- GSK$295
- Novo Nordisk$145
- AstraZeneca$123
- Otsuka America Pharmaceutical, Inc.$104
- plus $585 from 22 others
What the payments were for
- Food & beverage$2,36588%
- Education$32812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $1,010 |
| Astellas Pharma US Inc | 11 | $432 |
| GSK | 20 | $295 |
| Novo Nordisk | 9 | $145 |
| AstraZeneca | 10 | $123 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| Inspire Medical Systems, Inc. | 1 | $64 |
| Scilex Pharmaceuticals Inc. | 1 | $57 |
| Eisai Inc. | 4 | $55 |
| Kaleo, Inc. | 1 | $53 |
| Amarin Pharma, Inc. | 3 | $47 |
| Pfizer | 3 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Mylan Specialty L.p. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Abbott | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
How this compares
$2,694 in reported general payments places this provider in the 90th percentile of 2,542 general practice providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 142 | $219,656 |
| TrulicityDulaglutide | 79 | $120,017 |
| FarxigaDapagliflozin Propanediol | 141 | $113,443 |
| JanuviaSitagliptin Phosphate | 79 | $79,698 |
| EliquisApixaban | 106 | $77,374 |
| MyrbetriqMirabegron | 107 | $76,620 |
| OzempicSemaglutide | 47 | $61,437 |
| VascepaIcosapent Ethyl | 147 | $56,385 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $38,049 |
| JardianceEmpagliflozin | 38 | $35,304 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $31,975 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,370 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $21,610 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $21,357 |
| Metformin Er GastricMetformin Hcl | 13 | $17,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess, Synthroid | $1,010 | $245,034259 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $123 | $122,950156 claims |
| Lilly USA, LLCTrulicity | $14 | $120,01779 claims |
| PfizerEliquis | $43 | $77,374106 claims |
| Astellas Pharma US IncMyrbetriq | $432 | $76,620107 claims |
| Novo NordiskOzempic | $145 | $61,43747 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $295 | $38,77466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,542 general practice providers in Georgia.
Other general practice in Gainesville
- Carlos TanGainesville$75K
- Kelley BrummettGainesville$14K
- Abbey LeeGainesville$8K
- Edward SchlisselMarietta$665K
- Peter VanstromTucker$424K
- Robert PauleyUnion City$155K
- Hoyt GazawayBuford$145K
- Stanton McKennaAtlanta$75K
- Michael BoydAugusta$67K
- Michael KatzAtlanta$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.